

Wayne C. Drevets, M.D.

Neuroscience, Janssen Research & Development, LLC
of Johnson & Johnson, Inc.



Dr. Drevets is Vice President and Disease Area Leader in Mood Disorders in the Neuroscience Therapeutic Area at Janssen Research & Development. He received a B.S. (Biology) degree from Wheaton College and an M.D. degree from the University of Kansas, and then completed residency training in psychiatry at Washington University School of Medicine (St. Louis). He then joined the Washington University Department of Psychiatry faculty, ultimately attaining the rank of Associate Professor with tenure. In 1996 he moved to the University of Pittsburgh as Associate Professor of Psychiatry and Radiology, and then in 2001 joined the National Institute of Mental Health (NIMH) as Chief of the Section on Neuroimaging in Mood and Anxiety Disorders. In

2009, Dr. Drevets became the founding President and Scientific Director of the Laureate Institute for Brain Research and the Oxley Chair in Neuroscience Research at University of Oklahoma Health Sciences Center, Department of Psychiatry. He joined Janssen in August 2012 as the first Disease Area Leader in Mood Disorders.

Dr. Drevets' research has focused on characterizing the pathophysiology of mood disorders, elucidating the mechanisms underlying antidepressant and mood stabilizing therapies, and discovery of novel therapeutics for mood disorders. At Janssen he built a new program for developing novel treatments for major depressive disorder and bipolar disorder, in which he oversees the strategy conception and execution from discovery through late development phases. Under Dr. Drevets leadership Janssen's Mood Disease Area has assembled the industry leading portfolio of novel therapeutics in mood disorders, and achieved the launch of their first drug, Spravato, for treatment resistant depression in 2019, and the advance to phase 3 of seltorexant as an adjunctive treatment for depression.

Dr. Drevets has published nearly 350 articles and chapters and has been cited more than 57,000 times in the scientific literature (H-Index = 110). He is a Fellow of the American College of Neuropsychopharmacology and a Member of the Society for Biological Psychiatry.